复可托对恶性肿瘤患者免疫功能、生活质量影响的临床观察

Clinical Observation on the Effect of Fuketuo on the Immune Function and Quality of Life of Patients with Malignant Tumor

目的:观察复可托对恶性肿瘤患者免疫功能、生活质量的影响。方法:将117例恶性肿瘤患者随机分为治疗组(60例)和对照组(57例),对照组给予最佳支持治疗,治疗组在此基础上给予复可托治疗连续6个月。观察并比较两组治疗前、治疗后2、4、6个月的外周血T淋巴细胞亚群的变化及生活质量评分。结果:治疗2个月后,治疗组CD3^+、CD4^+细胞比例、CD4^+/CD8^+较对照组显著升高(P<0.05),CD8^+细胞比例较治疗前下降,但差异无统计学意义(P>0.05);治疗4、6个月后,治疗组CD3^+、CD4^+细胞比例、CD4^+/CD8^+升高,CD8^+细胞比例下降,差异有统计学意义(P<0.05);治疗6个月后,治疗组的KPS评分改善有效率和体重改善有效率均显著高于对照组,差异有统计学意义(P<0.05)。两组均未见明显不良反应发生。结论:复可托能纠正恶性肿瘤患者外周血T淋巴细胞亚群功能紊乱,同时明显改善患者生活质量,减少体重下降,且安全性高。

Objective： To observe the effect of Fuketuo on the immune function and quality of life of patients with malignant tumor. Methods： 117 patients with malignant tumor were randomly divided into the treatment group （60 cases） and the control group （57 cases）. The control group was given the best supportive therapy. On the basis of control group, the treatment group was given Fuketuo therapy for 6 months. The changes of T lymphocyte subsets and the quality of life were evaluated at 2, 4 and 6 months after treatment. Results： Compared with the control group, the levels of CD3＋, CD4＋ and CD4＋/CD8＋ of treatment group were higher （P〈0.05）, the CDS＊ value was decreased, but no significant difference was found （P〉0.05）. At 4 and 6 months after treatment, the levels of CD3＋, CD4＋ and CD4＋/CD8＋ of treatment group were higher（P〈0.05）, CD8＋ value was lower（P〈0.05）. At 6 months after treatment, the improvement rate of KPS score and weight of treatment group were obviously higher than those of the control group （P〈0.05）. No obvious adverse drug reaction was found in both groups during treatment. Conclusion： Fuketuo could protect the disorder of peripheral blood T lymphocyte subsets in patients with malignant tumor and improve the quality of life with high safety.